Thomson Reuters, a US-based provider of information for businesses and professionals, recently announced at CPhI China 2008(1) the release of Newport Horizon Premium, designed specifically for professionals working in product selection, business development, competitive intelligence and API (Active Pharmaceutical Ingredient) sourcing. Their use by generic and OTC (Over the Counter) pharmaceutical companies and API manufacturers in China and worldwide will enable them to find the most appropriate product development opportunities more quickly.
The new solution, offered by the Scientific business of Thomson Reuters, is projected to help provide a competitive boost to China's pharmaceutical industry which has seen substantial growth in the generic and API sectors in recent years. Newport Horizon Premium combines sales, consumption, launch, patent, patent challenge, exclusivity, chemistry, prescribing and regulatory information for more than 10,000 molecules, 18,000 companies, 68 markets and 92 patent countries worldwide with unique, early API development and manufacturing intelligence. They build on the substantial success of Horizon Global, by adding patented and published routes of synthesis on thousands of molecules, with listed intermediates and reagents, sourced from Prous Science's respected Synthline database.
Newport Horizon Premium also has kilogram and IU (International Units) API consumption data from IMS Health added to the data and capabilities already available. This data is now available for thousands of drugs by region and by dose form for both the current and previous year and allow customers to evaluate scale, consumption trends and prices for active ingredients, all of which can be difficult to estimate using sales data alone.
The new solution addresses the needs of large and small players in the pharmaceuticals market and features powerful multi-criteria search functionalities. Newport Horizon Premium is aimed at helping generic, OTC and API companies in their constant struggle to build deals faster and accelerate time to market.
